Bijan Boldajipour
Overview
Explore the profile of Bijan Boldajipour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1897
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boldajipour B, Lee G, Albertson T
N Engl J Med
. 2023 Jun;
388(24):2303.
PMID: 37314724
No abstract available.
2.
Metelo A, Jozwik A, Luong L, Dominey-Foy D, Graham C, Attwood C, et al.
Cancer Res Commun
. 2023 Mar;
2(3):158-171.
PMID: 36874402
Significance: Multiple myeloma is an incurable cancer of the plasma cells. A new therapy with anti-BCMA CAR T cells - the patient's own T cells genetically engineered to find and...
3.
Lin R, Nager A, Park S, Sutton J, Lay C, Melton Z, et al.
Cancer Immunol Res
. 2022 Jul;
10(9):1069-1083.
PMID: 35881865
Although cytokine support can enhance CAR T-cell function, coadministering cytokines or engineering CAR T cells to secrete cytokines can result in toxicities. To mitigate these safety risks, we engineered iTurboCAR...
4.
Park S, Pascua E, Lindquist K, Kimberlin C, Deng X, Mak Y, et al.
Nat Commun
. 2021 Jan;
12(1):710.
PMID: 33514714
Antibody-based therapeutics have experienced a rapid growth in recent years and are now utilized in various modalities spanning from conventional antibodies, antibody-drug conjugates, bispecific antibodies to chimeric antigen receptor (CAR)...
5.
Sommer C, Boldajipour B, Kuo T, Bentley T, Sutton J, Chen A, et al.
Mol Ther
. 2019 Apr;
27(6):1126-1138.
PMID: 31005597
Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological...
6.
Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, et al.
Sci Rep
. 2018 Jun;
8(1):8972.
PMID: 29895885
CAR T-cell therapies hold great promise for treating a range of malignancies but are however challenged by the complexity of their production and by the adverse events related to their...
7.
Broz M, Binnewies M, Boldajipour B, Nelson A, Pollack J, Erle D, et al.
Cancer Cell
. 2017 Sep;
26(6):938.
PMID: 28898680
No abstract available.
8.
Boldajipour B, Nelson A, Krummel M
JCI Insight
. 2016 Dec;
1(20):e89289.
PMID: 27942588
T cells that enter tumors are largely tolerized, but how that process is choreographed and how the ensuing "dysfunctional" tumor-infiltrating lymphocytes (TILs) are maintained are poorly understood and are difficult...
9.
Plaks V, Boldajipour B, Linnemann J, Nguyen N, Kersten K, Wolf Y, et al.
Dev Cell
. 2015 Sep;
34(5):493-504.
PMID: 26321127
Postnatal organogenesis occurs in an immune competent environment and is tightly controlled by interplay between positive and negative regulators. Innate immune cells have beneficial roles in postnatal tissue remodeling, but...
10.
Broz M, Binnewies M, Boldajipour B, Nelson A, Pollack J, Erle D, et al.
Cancer Cell
. 2014 Dec;
26(5):638-52.
PMID: 25446897
It is well understood that antigen-presenting cells (APCs) within tumors typically do not maintain cytotoxic T cell (CTL) function, despite engaging them. Across multiple mouse tumor models and human tumor...